CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 194 enrolled
Drug / intervention
Dihydroartemisinin-piperaquinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04487145
NCT04487145Phase 4Completed
CompareCT.gov

DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

University of California, San Francisco·interventional·Posted Jul 27, 2020·Updated Mar 14, 2025

In Brief

A Phase 4 clinical trial evaluating Dihydroartemisinin-piperaquine for Drug-Drug Interaction and HIV Infection. Completed, enrolled 194 participants across 2 sites.

Detailed Summary

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART) and HIV-uninfected children not on ART. All children will be malaria-uninfected at the time of enrollment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug-Drug Interaction, HIV Infection
CountriesUganda
CollaboratorsYale University, Makerere University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 27, 2020
Enrollment StartNov 23, 2020
Primary CompletionApr 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.9 years ago

Interventions

Dihydroartemisinin-piperaquinedrug

It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.